SG11201702810TA - Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis - Google Patents
Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosisInfo
- Publication number
- SG11201702810TA SG11201702810TA SG11201702810TA SG11201702810TA SG11201702810TA SG 11201702810T A SG11201702810T A SG 11201702810TA SG 11201702810T A SG11201702810T A SG 11201702810TA SG 11201702810T A SG11201702810T A SG 11201702810TA SG 11201702810T A SG11201702810T A SG 11201702810TA
- Authority
- SG
- Singapore
- Prior art keywords
- osteoporosis
- prevention
- treatment
- pharmaceutical compositions
- carboxylate compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/86—Unsaturated compounds containing keto groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462062660P | 2014-10-10 | 2014-10-10 | |
| PCT/CA2015/000530 WO2016054725A1 (en) | 2014-10-10 | 2015-10-08 | Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201702810TA true SG11201702810TA (en) | 2017-05-30 |
Family
ID=55652426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702810TA SG11201702810TA (en) | 2014-10-10 | 2015-10-08 | Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10925846B2 (enExample) |
| EP (1) | EP3204000B1 (enExample) |
| JP (1) | JP6700638B2 (enExample) |
| KR (1) | KR20170066613A (enExample) |
| CN (1) | CN106999459B (enExample) |
| AR (1) | AR102247A1 (enExample) |
| AU (1) | AU2015330642B2 (enExample) |
| BR (1) | BR112017007386A2 (enExample) |
| CA (1) | CA2963358C (enExample) |
| DK (1) | DK3204000T3 (enExample) |
| ES (1) | ES2794782T3 (enExample) |
| IL (1) | IL251409B (enExample) |
| MX (1) | MX376880B (enExample) |
| MY (1) | MY187511A (enExample) |
| PH (1) | PH12017500636A1 (enExample) |
| PL (1) | PL3204000T3 (enExample) |
| PT (1) | PT3204000T (enExample) |
| RU (1) | RU2712027C2 (enExample) |
| SG (1) | SG11201702810TA (enExample) |
| TW (1) | TWI723962B (enExample) |
| UY (1) | UY36355A (enExample) |
| WO (1) | WO2016054725A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3203999T3 (pl) * | 2014-10-10 | 2020-07-27 | Liminal Biosciences Limited | Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia osteoporozy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200720256A (en) * | 2005-05-13 | 2007-06-01 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
| CA2777629C (en) * | 2009-10-14 | 2018-02-13 | The Governors Of The University Of Alberta | Compounds having peptides conjugated to bone targeting moieties and methods of making and using thereof |
| US20130225683A1 (en) * | 2010-10-27 | 2013-08-29 | Prometic Biosciences Inc. | Compounds and Pharmaceutical Compositions for Uses in Diabetes |
| PH12013500763B1 (en) * | 2010-10-27 | 2018-07-04 | Prometic Pharma Smt Ltd | Phenylketone carboxylate compounds and pharmaceutical uses thereof |
| CN105997967B (zh) * | 2010-10-27 | 2019-08-23 | 普罗米蒂克医药Smt有限公司 | 用于治疗癌症的化合物和组合物 |
| WO2014138372A1 (en) * | 2013-03-06 | 2014-09-12 | Primavera Biosciences, Inc. | Composition and method for treating osteoarthritis |
| PL3203999T3 (pl) * | 2014-10-10 | 2020-07-27 | Liminal Biosciences Limited | Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia osteoporozy |
-
2015
- 2015-10-08 WO PCT/CA2015/000530 patent/WO2016054725A1/en not_active Ceased
- 2015-10-08 SG SG11201702810TA patent/SG11201702810TA/en unknown
- 2015-10-08 ES ES15849766T patent/ES2794782T3/es active Active
- 2015-10-08 JP JP2017518894A patent/JP6700638B2/ja not_active Expired - Fee Related
- 2015-10-08 KR KR1020177012549A patent/KR20170066613A/ko not_active Ceased
- 2015-10-08 BR BR112017007386-2A patent/BR112017007386A2/pt not_active Application Discontinuation
- 2015-10-08 TW TW104133246A patent/TWI723962B/zh not_active IP Right Cessation
- 2015-10-08 CN CN201580066144.XA patent/CN106999459B/zh not_active Expired - Fee Related
- 2015-10-08 MX MX2017004735A patent/MX376880B/es active IP Right Grant
- 2015-10-08 DK DK15849766.9T patent/DK3204000T3/da active
- 2015-10-08 PL PL15849766T patent/PL3204000T3/pl unknown
- 2015-10-08 US US15/516,635 patent/US10925846B2/en not_active Expired - Fee Related
- 2015-10-08 EP EP15849766.9A patent/EP3204000B1/en active Active
- 2015-10-08 MY MYPI2017000530A patent/MY187511A/en unknown
- 2015-10-08 AU AU2015330642A patent/AU2015330642B2/en not_active Ceased
- 2015-10-08 PT PT158497669T patent/PT3204000T/pt unknown
- 2015-10-08 CA CA2963358A patent/CA2963358C/en active Active
- 2015-10-08 RU RU2017116154A patent/RU2712027C2/ru active
- 2015-10-13 UY UY0001036355A patent/UY36355A/es not_active Application Discontinuation
- 2015-10-13 AR ARP150103295A patent/AR102247A1/es unknown
-
2017
- 2017-03-27 IL IL251409A patent/IL251409B/en active IP Right Grant
- 2017-04-06 PH PH12017500636A patent/PH12017500636A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2963358A1 (en) | 2016-04-14 |
| TW201618761A (zh) | 2016-06-01 |
| IL251409B (en) | 2020-08-31 |
| UY36355A (es) | 2016-06-01 |
| CN106999459B (zh) | 2020-07-10 |
| PT3204000T (pt) | 2020-05-06 |
| RU2017116154A (ru) | 2018-11-12 |
| AU2015330642A1 (en) | 2017-05-11 |
| BR112017007386A2 (pt) | 2018-01-23 |
| PH12017500636A1 (en) | 2017-09-25 |
| ES2794782T3 (es) | 2020-11-19 |
| CN106999459A (zh) | 2017-08-01 |
| EP3204000B1 (en) | 2020-01-08 |
| TWI723962B (zh) | 2021-04-11 |
| DK3204000T3 (da) | 2020-04-06 |
| WO2016054725A1 (en) | 2016-04-14 |
| IL251409A0 (en) | 2017-05-29 |
| EP3204000A1 (en) | 2017-08-16 |
| AR102247A1 (es) | 2017-02-15 |
| JP6700638B2 (ja) | 2020-05-27 |
| US20190038580A1 (en) | 2019-02-07 |
| CA2963358C (en) | 2023-03-07 |
| RU2712027C2 (ru) | 2020-01-27 |
| MX376880B (es) | 2025-03-07 |
| PL3204000T3 (pl) | 2020-07-27 |
| KR20170066613A (ko) | 2017-06-14 |
| JP2017530179A (ja) | 2017-10-12 |
| MY187511A (en) | 2021-09-24 |
| US10925846B2 (en) | 2021-02-23 |
| AU2015330642B2 (en) | 2019-07-04 |
| EP3204000A4 (en) | 2018-06-20 |
| RU2017116154A3 (enExample) | 2019-05-06 |
| MX2017004735A (es) | 2017-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3142707A4 (en) | Methods and compositions for prevention or treatment of a disease | |
| IL252477A0 (en) | 2-aminopyrimidine compound, pharmaceutical structure and its use | |
| EP3104706A4 (en) | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | |
| IL261444A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| SMT202100441T1 (it) | Composizioni di composti e loro usi | |
| EP3182989A4 (en) | Methods and compositions for the prevention and treatment of disease | |
| EP3102200A4 (en) | Therapeutic compounds and compositions | |
| PL3130353T3 (pl) | Kompozycja farmaceutyczna na bazie nanostruktury grafenu do zapobiegania lub leczenia chorób neurodegeneracyjnych | |
| ZA201702639B (en) | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | |
| SG11201702554QA (en) | Compositions and methods for the treatment of multiple sclerosis | |
| GB201401086D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL248210A0 (en) | Methods and preparations for the treatment of blood vessel malformations | |
| IL261278A (en) | Pharmaceutical compositions for the treatment of cancer | |
| IL257336B (en) | Pharmaceutical compounds and preparations for the prevention or treatment of parasitic diseases | |
| EP3107534A4 (en) | Compositions and methods for the treatment of neurodegenerative diseases | |
| SG11201702812PA (en) | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes | |
| EP3131635A4 (en) | Compositions and methods for the treatment or prevention of neurodegenerative disorders | |
| EP3219323B8 (en) | Pharmaceutical composition for treatment and/or prevention of hepatitis c | |
| IL251409A0 (en) | Compounds of phenylketone carboxylate and their pharmaceutical preparations for the prevention and treatment of osteoporosis | |
| EP3253379A4 (en) | Pharmaceutical composition for the treatment of obesity | |
| EP3322435A4 (en) | Pharmaceutical compositions useful for the treatment of tissue injury | |
| ZA201500995B (en) | Low dose pharmaceutical composition | |
| PL3164110T3 (pl) | Kompozycje farmaceutyczne do leczenia łuszczycy | |
| EP3104940A4 (en) | Compositions and methods for the prevention and/or treatment of schistosomiasis | |
| GB201714241D0 (en) | Pharmaceutical compositions for the treatment of proteinopathies |